CATHERINE THYRA SAM MD
Prescription History 1710949839
Obstetrics & Gynecology in Lafayette, IN

NPI Status: Active since April 04, 2006

Contact Information

3920 ST FRANCIS WAY STE 100
LAFAYETTE, IN
ZIP 47905
Phone: (765) 428-5990
Fax: (765) 428-5896

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CATHERINE THYRA SAM MD, an active Obstetrics & Gynecology specialist practicing in Lafayette, IN. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 106 documented patient claims. Among these therapy options, the most frequently utilized medication is Solifenacin Succinate, which accounts for 28 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 15
30-Day Fills 42.0
Days Supply 1,260
IN State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills108.5
Peer Average Days Supply3,195
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $141.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.44

State Avg Cost Per Claim

$10.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 27
30-Day Fills 73.9
Days Supply 2,217
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills65.0
Peer Average Days Supply1,930
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $720.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.67

State Avg Cost Per Claim

$55.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Medroxyprogesterone Acetate

Generic Formulation: Medroxyprogesterone AcetateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 22
30-Day Fills 32.0
Days Supply 915
IN State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply968
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $231.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.50

State Avg Cost Per Claim

$30.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.

Therapeutic Applications

This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 26.0
Days Supply 780
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,851
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $350.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.03

State Avg Cost Per Claim

$41.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Solifenacin Succinate

Generic Formulation: Solifenacin SuccinateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 28
30-Day Fills 56.0
Days Supply 1,680
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills53.1
Peer Average Days Supply1,501
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,221.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$186.50

State Avg Cost Per Claim

$77.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Therapeutic Applications

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CATHERINE THYRA SAM MD provides transparency into local medical care patterns within Lafayette, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.